A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

被引：3

作者：

Palomba, M. Lia ^{[1
]}

Ghione, Paola ^{[2
,3
]}

Patel, Anik R. ^{[4
]}

Deighton, Kevin ^{[5
]}

Jacobson, Caron ^{[6
]}

Nahas, Myrna ^{[4
]}

Jung, A. Scott ^{[4
]}

Hatswell, Anthony J. ^{[5
]}

Kanters, Steve ^{[7
]}

Limbrick-Oldfield, Eve ^{[7
]}

Wade, Sally W. ^{[8
]}

Snider, Julia Thornton ^{[4
]}

Neelapu, Sattva S. ^{[9
]}

Riberio, Maria Teresa ^{[10
]}

Gribben, John ^{[11
]}

Radford, John ^{[12
]}

Bobillo, Sabela ^{[13
]}

Ghesquieres, Herve ^{[14
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, New York, NY USA

[3] Roswell Pk Comprehens Canc Ctr, Dept Med, Buffalo, NY USA

[4] Gilead Co, Kite, Santa Monica, CA USA

[5] Delta Hat, Nottingham, England

[6] Dana Farber Canc Ctr, Dept Med, Boston, MA USA

[7] RainCity Analyt, Vancouver, BC, Canada

[8] Wade Outcomes Res Consulting, Salt Lake City, UT USA

[9] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[10] Portuguese Oncol Inst Porto, Porto, Portugal

[11] Univ London, Barts Canc Inst, Barts & London Sch Med, Queen Mary, London, England

[12] Christie NHS Fdn Trust, Manchester Canc Res Ctr & Manchester Acad Hlth Sc, Manchester, Lancs, England

[13] Hebron Inst Oncol VHIO, Expt Hematol, Barcelona, Spain

[14] Univ Claude Bernard Lyon 1, Dept Hematol, Ctr Hosp Lyon Sud, Pierre Benite, France

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-147608

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3543

引用

页数：6

共 49 条

[1] A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)
Ghione, Paola
Palomba, Maria Lia
Ray, Markqayne D.
Limbrick-Oldfield, Eve H.
Owen, Jess
Kanters, Steve
Bobillo, Sabela
Ribeiro, Maria Teresa
Jacobson, Caron A.
Neelapu, Sattva S.
Ghesquieres, Herve
Nahas, Myrna
Beygi, Sara
Patel, Anik R.
Gribben, John G.
BLOOD, 2022, 140 : 4676 - 4677
[2] An Updated Comparison of Clinical Outcomes from 4-Year Follow-up of Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma
Gribben, John G.
Ghione, Paola
Palomba, Maria Lia
Ray, Markqayne D.
Limbrick-Oldfield, Eve H.
Kanters, Steve
Bobillo, Sabela
Ribiero, Maria Teresa
Jacobson, Caron A.
Neelapu, Sattva S.
Ghesquieres, Herve
Nikolajeva, Olga
Yan, Jiali
Wang, Hailin
Patel, Anik R.
BLOOD, 2023, 142
[3] A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma
Ghione, Paola
Palomba, M. Lia
Ray, Markqayne D.
Limbrick-Oldfield, Eve H.
Owen, Jessica
Kanters, Steve
Bobillo, Sabela
Ribiero, Maria Teresa
Jacobson, Caron A.
Neelapu, Sattva S.
Ghesquieres, Herve
Nahas, Myrna
Beygi, Sara
Patel, Anik R.
Gribben, John G.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (05):
[4] Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
Ghione, Paola
Palomba, M. Lia
Patel, Anik R.
Bobillo, Sabela
Deighton, Kevin
Jacobson, Caron A.
Nahas, Myrna
Hatswell, Anthony J.
Jung, A. Scott
Kanters, Steve
Snider, Julia Thornton
Neelapu, Sattva S.
Ribeiro, Maria Teresa
Brookhart, M. Alan
Ghesquieres, Herve
Radford, John
Gribben, John G.
BLOOD, 2022, 140 (08) : 851 - 860
[5] A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
Palomba, M. Lia
Ghione, Paola
Patel, Anik R.
Nahas, Myrna
Beygi, Sara
Hatswell, Anthony J.
Kanters, Steve
Limbrick-Oldfield, Eve H.
Wade, Sally W.
Ray, Markqayne D.
Owen, Jessica
Neelapu, Sattva S.
Gribben, John
Radford, John
Bobillo, Sabela
EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (02) : 199 - 206
[6] Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).
Jacobson, Caron Alyce
Hemmer, Michael T.
Hu, Zhen-Huan
Frank, Matthew Joshua
Popplewell, Leslie
Ahmed, Nausheen
Lin, Yi
Best, Timothy
Beygi, Sara
Miao, Harry H.
Fu, Christine
Sun, Fang
Xu, Hairong
Pasquini, Marcelo C.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Retreatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 11 - 13
[8] Retreatment with axicabtagene ciloleucel in patients with relapsed/refractory Indolent non-Hodgkin lymphoma in ZUMA-5
Chavez, Julio C.
Jacobson, Caron A.
Sehgal, Alison R.
Neelapu, Sattva S.
Maloney, David G.
Salles, Gilles
William, Basem M.
Yang, Yin
Goyal, Lovely
Chou, Justin
Plaks, Vicki
Avanzi, Mauro P.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 148 - 149
[9] Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study
Ghione, Paola
Palomba, Maria Lia
Ghesquieres, Herve
Bobillo, Sabela
Patel, Anik R.
Nahas, Myrna
Kanters, Steve
Deighton, Kevin
Hatswell, Anthony
Ma, Long
Oldfield, Eve H. Limbrick-
Snider, Julia Thornton
Wade, Sally W.
Riberio, Maria Teresa
Radford, John
Beygi, Sara
Gribben, John
HAEMATOLOGICA, 2023, 108 (03) : 822 - 832
[10] Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5
Chavez, Julio C.
Jacobson, Caron A.
Sehgal, Alison R.
Neelapu, Sattva S.
Maloney, David G.
Salles, Gilles
William, Basem M.
Yang, Yin
Goyal, Lovely
Chou, Justin
Plaks, Vicki
Avanzi, Mauro P.
BLOOD, 2020, 136

← 1 2 3 4 5 →